3-甲氧基-N-(甲氧基甲基)苯胺 | 253597-52-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基-N-(甲氧基甲基)苯胺
• 英文名称: 3-methoxy-N-(methoxymethyl)aniline
• CAS: 253597-52-3
• 化学式: C₉H₁₃NO₂
• 分子量: 167.2
• InChiKey: HMKAOFLTPLZDBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲氧基-N-(甲氧基甲基)苯胺 、 甲醇 、 硼氢化钠 生成 N-甲基-3-甲氧基苯胺
  参考文献：
  名称：

  BARLUENGA, J.;BAYON, A. M.;ASENSIO, G., J. CHEM. SOC. CHEM. COMMUN., 1984, N 20, 1334-1335

  摘要：

  DOI：

文献信息

• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20080039449A1

  公开（公告）日：2008-02-14

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing-N-acylamino compounds.

  本发明涉及一种新型的化合物类别，其为白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以作为抗IL-1、凋亡、IGIF、IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、感染性疾病、退行性疾病和坏死性疾病的药物。本发明还涉及使用这些化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、降低IGIF和IFN-γ的产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Batchelor Mark James

  公开号：US20110178069A1

  公开（公告）日：2011-07-21

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、减少IGIF和IFN-γ产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。
• US7790713B2
  申请人：——

  公开号：US7790713B2

  公开（公告）日：2010-09-07
• US8119631B2
  申请人：——

  公开号：US8119631B2

  公开（公告）日：2012-02-21
• BARLUENGA, J.;BAYON, A. M.;ASENSIO, G., J. CHEM. SOC. CHEM. COMMUN., 1984, N 20, 1334-1335
  作者：BARLUENGA, J.、BAYON, A. M.、ASENSIO, G.

  DOI：——

  日期：——